[{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-34712","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience","highestDevelopmentStatusID":"5","companyTruncated":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience"},{"orgOrder":0,"company":"GSK","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPR301","moa":"GCase85","graph1":"Neurology","graph2":"IND Enabling","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pheno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTD802","moa":"GPR17","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pheno Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pheno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0005","moa":"IL-6 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"4D Pharma \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PTD802 is a novel small molecule therapeutic designed to promote remyelination by inhibiting GPR17. It is being investigated for multiple sclerosis.

                          Product Name : PTD802

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : PTD802

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPR301 is an AAV9 capsid which can counteract the reduced GCase activity caused by these mutations, potentially providing a gene therapy that changes the lives of people with GBA1 Parkinson’s disease.

                          Product Name : SPR301

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : SPR301

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb that is being evaluated in patients with moderate Alzheimer’s disease.

                          Product Name : TZLS-401

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 26, 2024

                          Lead Product(s) : Foralumab

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response to treat Neuropathic Corneal Pain.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          September 10, 2023

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with alzheimer’s disease.

                          Product Name : TZLS-401

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 15, 2023

                          Lead Product(s) : Foralumab

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The agreement aims to evaluate the efficacy and safety of OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, in patients with neuropathic corneal pain.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          July 28, 2023

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Tufts Medical Center

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : MTX325 is a USP30 inhibitor small molecule drug candidate, which is currently being evaluated in clinical trial studies with patients for the treatment of parkinson's disease.

                          Product Name : MTX325

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : MTX325

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Lead Product(s) : BEN-34712

                          Therapeutic Area : Neurology

                          Study Phase : IND Enabling

                          Sponsor : The Sheffield Institute for Translational Neuroscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies for amyotrophic lateral sclerosis.

                          Product Name : BEN-34712

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 06, 2023

                          Lead Product(s) : BEN-34712

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : The Sheffield Institute for Translational Neuroscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : IND clearance marks the expansion of the comany's pipeline single strain Live Biotherapeutics of MRx0005 and MRx0029 in development for the treatment of neurodegenerative conditions such as Parkinson’s disease via the gut-brain axis.

                          Product Name : MRx0005

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 22, 2022

                          Lead Product(s) : MRx0005

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, SciNeuro will receive a worldwide license to intellectual property covering certain GSK Lp-PLA2 inhibitors including SNP318 and will be responsible for their further development through clinical proof-of-concept (PoC).

                          Product Name : SNP318

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 06, 2022

                          Lead Product(s) : SNP318

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : SciNeuro Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank